Pfizer/$PFE

13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Ticker

$PFE

Primary listing

NYSE

Industry

Pharmaceuticals

Employees

81,000

ISIN

US7170811035

Pfizer Metrics

BasicAdvanced
$136B
17.26
$1.38
0.50
$1.70
7.20%

What the Analysts think about Pfizer

Analyst ratings (Buy, Hold, Sell) for Pfizer stock.

Bulls say / Bears say

Pfizer's acquisition of Seagen for $43 billion enhances its oncology portfolio, positioning the company for significant growth in the cancer treatment market. (investing.com)
The European Commission's approval of Pfizer's RSV vaccine, ABRYSVO®, for adults aged 18 to 59 at increased risk, expands the company's vaccine offerings and potential revenue streams. (businesswire.com)
Pfizer's licensing agreement with China's 3SBio for the experimental cancer drug SSGJ-707, including a $1.25 billion upfront payment and potential $4.8 billion in milestones, strengthens its oncology pipeline and global presence. (reuters.com)
The U.S. House Judiciary Committee's investigation into allegations that Pfizer delayed COVID-19 vaccine trial results to influence the 2020 presidential election could damage the company's reputation and lead to legal challenges. (reuters.com)
Pfizer's first-quarter 2025 revenue of $13.72 billion missed expectations, primarily due to a significant decline in Paxlovid sales, indicating potential challenges in maintaining revenue growth post-pandemic. (reuters.com)
The nomination of vaccine skeptic Robert F. Kennedy Jr. as U.S. health secretary poses a potential threat to Pfizer's vaccine sales, as his views could influence public perception and policy decisions. (bloomberg.com)
Data summarised monthly by Lightyear AI. Last updated on 22 May 2025.

Pfizer Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Pfizer Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PFE

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs